Amgen's Dividend Growth Cooling as Patent Cliffs and Price Controls Bite

What happened

Amgen has raised its dividend every year since 2011, with cumulative growth of about 800%, but the rate of increases has decelerated as the company faces patent expiries and drug pricing pressure. The article highlights that the next dividend increase, expected soon, may be smaller than historical raises as management balances shareholder returns with the need to fund pipeline and debt reduction. This aligns with the master report's identification of accelerating price erosion on ENBREL, the $1.2B Otezla impairment from IRA price setting, and upcoming biosimilar competition for Prolia/XGEVA. Filings show non-GAAP operating margin remains strong around 47%, but rising R&D, capex of ~$2.6B in 2026, and unresolved tax disputes constrain free cash flow available for dividends. The company's leverage remains elevated at ~3.2x-4.1x net debt/EBITDA, and management has prioritized debt repayment over buybacks, suggesting dividend growth may take a back seat to balance sheet repair.

Implication

Income-focused investors should not assume the historical ~10%+ annual dividend raises will continue; the next increase may be modest and future growth could stall if cash flow weakens. The dividend cut risk remains low given Amgen's strong free cash flow generation, but payout ratio may creep higher if earnings decline due to price erosion, limiting flexibility. For total-return investors, the stock's premium valuation (~23.7x earnings) already prices in sustained growth, leaving little margin of safety if the dividend growth slowdown signals broader franchise deterioration. The master report's base case implies fair value around $340, close to current price, with bear case at $270 if policy and biosimilar pressures intensify, so risk-reward remains unfavorable. We recommend trimming positions above $370 and waiting for a pullback toward $295, where the dividend yield and total return profile would be more attractive relative to risks.

Thesis delta

The article does not change our fundamental thesis but confirms our wary stance on Amgen's income outlook. While the dividend track record is impressive, the decelerating pace of increases is consistent with the earnings headwinds we have identified from IRA price cuts, biosimilars, and high leverage. We maintain our 'POTENTIAL SELL' rating and prefer to wait for a more attractive entry point.